Cargando…

A Variable Height Microfluidic Device for Multiplexed Immunoassay Analysis of Traumatic Brain Injury Biomarkers

Traumatic brain injury (TBI) is a leading cause of global morbidity and mortality, partially due to the lack of sensitive diagnostic methods and efficacious therapies. Panels of protein biomarkers have been proposed as a way of diagnosing and monitoring TBI. To measure multiple TBI biomarkers simult...

Descripción completa

Detalles Bibliográficos
Autores principales: Krausz, Alyse D., Korley, Frederick K., Burns, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472232/
https://www.ncbi.nlm.nih.gov/pubmed/34562910
http://dx.doi.org/10.3390/bios11090320
_version_ 1784574676092059648
author Krausz, Alyse D.
Korley, Frederick K.
Burns, Mark A.
author_facet Krausz, Alyse D.
Korley, Frederick K.
Burns, Mark A.
author_sort Krausz, Alyse D.
collection PubMed
description Traumatic brain injury (TBI) is a leading cause of global morbidity and mortality, partially due to the lack of sensitive diagnostic methods and efficacious therapies. Panels of protein biomarkers have been proposed as a way of diagnosing and monitoring TBI. To measure multiple TBI biomarkers simultaneously, we present a variable height microfluidic device consisting of a single channel that varies in height between the inlet and outlet and can passively multiplex bead-based immunoassays by trapping assay beads at the point where their diameter matches the channel height. We developed bead-based quantum dot-linked immunosorbent assays (QLISAs) for interleukin-6 (IL-6), glial fibrillary acidic protein (GFAP), and interleukin-8 (IL-8) using Dynabeads(TM) M-450, M-270, and MyOne(TM), respectively. The IL-6 and GFAP QLISAs were successfully multiplexed using a variable height channel that ranged in height from ~7.6 µm at the inlet to ~2.1 µm at the outlet. The IL-6, GFAP, and IL-8 QLISAs were also multiplexed using a channel that ranged in height from ~6.3 µm at the inlet to ~0.9 µm at the outlet. Our system can keep pace with TBI biomarker discovery and validation, as additional protein biomarkers can be multiplexed simply by adding in antibody-conjugated beads of different diameters.
format Online
Article
Text
id pubmed-8472232
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84722322021-09-28 A Variable Height Microfluidic Device for Multiplexed Immunoassay Analysis of Traumatic Brain Injury Biomarkers Krausz, Alyse D. Korley, Frederick K. Burns, Mark A. Biosensors (Basel) Article Traumatic brain injury (TBI) is a leading cause of global morbidity and mortality, partially due to the lack of sensitive diagnostic methods and efficacious therapies. Panels of protein biomarkers have been proposed as a way of diagnosing and monitoring TBI. To measure multiple TBI biomarkers simultaneously, we present a variable height microfluidic device consisting of a single channel that varies in height between the inlet and outlet and can passively multiplex bead-based immunoassays by trapping assay beads at the point where their diameter matches the channel height. We developed bead-based quantum dot-linked immunosorbent assays (QLISAs) for interleukin-6 (IL-6), glial fibrillary acidic protein (GFAP), and interleukin-8 (IL-8) using Dynabeads(TM) M-450, M-270, and MyOne(TM), respectively. The IL-6 and GFAP QLISAs were successfully multiplexed using a variable height channel that ranged in height from ~7.6 µm at the inlet to ~2.1 µm at the outlet. The IL-6, GFAP, and IL-8 QLISAs were also multiplexed using a channel that ranged in height from ~6.3 µm at the inlet to ~0.9 µm at the outlet. Our system can keep pace with TBI biomarker discovery and validation, as additional protein biomarkers can be multiplexed simply by adding in antibody-conjugated beads of different diameters. MDPI 2021-09-07 /pmc/articles/PMC8472232/ /pubmed/34562910 http://dx.doi.org/10.3390/bios11090320 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Krausz, Alyse D.
Korley, Frederick K.
Burns, Mark A.
A Variable Height Microfluidic Device for Multiplexed Immunoassay Analysis of Traumatic Brain Injury Biomarkers
title A Variable Height Microfluidic Device for Multiplexed Immunoassay Analysis of Traumatic Brain Injury Biomarkers
title_full A Variable Height Microfluidic Device for Multiplexed Immunoassay Analysis of Traumatic Brain Injury Biomarkers
title_fullStr A Variable Height Microfluidic Device for Multiplexed Immunoassay Analysis of Traumatic Brain Injury Biomarkers
title_full_unstemmed A Variable Height Microfluidic Device for Multiplexed Immunoassay Analysis of Traumatic Brain Injury Biomarkers
title_short A Variable Height Microfluidic Device for Multiplexed Immunoassay Analysis of Traumatic Brain Injury Biomarkers
title_sort variable height microfluidic device for multiplexed immunoassay analysis of traumatic brain injury biomarkers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472232/
https://www.ncbi.nlm.nih.gov/pubmed/34562910
http://dx.doi.org/10.3390/bios11090320
work_keys_str_mv AT krauszalysed avariableheightmicrofluidicdeviceformultiplexedimmunoassayanalysisoftraumaticbraininjurybiomarkers
AT korleyfrederickk avariableheightmicrofluidicdeviceformultiplexedimmunoassayanalysisoftraumaticbraininjurybiomarkers
AT burnsmarka avariableheightmicrofluidicdeviceformultiplexedimmunoassayanalysisoftraumaticbraininjurybiomarkers
AT krauszalysed variableheightmicrofluidicdeviceformultiplexedimmunoassayanalysisoftraumaticbraininjurybiomarkers
AT korleyfrederickk variableheightmicrofluidicdeviceformultiplexedimmunoassayanalysisoftraumaticbraininjurybiomarkers
AT burnsmarka variableheightmicrofluidicdeviceformultiplexedimmunoassayanalysisoftraumaticbraininjurybiomarkers